Appropriate use of NSAIDs: Considering cardiovascular risk in the elderly

Geriatrics

Volumn 62, Issue 3, 2007, Pages 16-21

  Stillman, Martin J ^a,b   Stillman, M Thomas ^a,b  

^a HENNEPIN COUNTY MEDICAL CENTER   (United States)

^b UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

Author keywords

Aspirin; Cardiovascular toxicity adverse effects; Clinical use pathway; COX 2 inhibitors (coxibs); Hypertension; Nonsteroidal anti inflammatory drugs (NSAIDs)

Indexed keywords

ACETYLSALICYLIC ACID; CELECOXIB; CYCLOOXYGENASE 2 INHIBITOR; DICLOFENAC; IBUPROFEN; LUMIRACOXIB; NAPROXEN; NONSTEROID ANTIINFLAMMATORY AGENT; ROFECOXIB;

AGING; ALGORITHM; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CLINICAL PRACTICE; CONGESTIVE HEART FAILURE; DECISION MAKING; DRUG EFFICACY; DRUG SAFETY; DRUG SELECTIVITY; DRUG WITHDRAWAL; EDEMA; GASTROINTESTINAL SYMPTOM; HEART DEATH; HEART INFARCTION; HEART PROTECTION; HUMAN; HYPERTENSION; MORTALITY; OSTEOARTHRITIS; PERIPHERAL EDEMA; REVIEW; RISK BENEFIT ANALYSIS; RISK REDUCTION; SIDE EFFECT; SYSTEMATIC REVIEW; SYSTOLIC BLOOD PRESSURE;

AGED; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ASPIRIN; CARDIOVASCULAR DISEASES; CYCLOOXYGENASE 2 INHIBITORS; DRUG EVALUATION; DRUG INTERACTIONS; EDEMA; GERIATRICS; HEART FAILURE, CONGESTIVE; HUMANS; HYPERTENSION; MYOCARDIAL INFARCTION; PRACTICE GUIDELINES; RISK ASSESSMENT;

EID: 33947423957     PISSN: 0016867X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (28)

1. Whelton A, White WB, Bello AE, Puma JA, Fort JG; SUCCESS-VII investigators. Effects of celecoxib and rofecoxib on blood pressure and edema in patients > or = 65 years of age with systemic hypertension and osteoarthritis. Am J Cardiol 2002; 90(9):959-63.
2. Sowers JR, White WB, Pitt B, et al. The effects of cyclooxygenase-2 inhibitors and nonsteroidal anti-inflammatory therapy on 24-hour blood pressure in patients with hypertension, osteoarthritis, and type 2 diabetes mellitus. Arch Intern Med 2005; 165(2):161-8.
3. Solomon OH, Schneeweiss S, Levin R, Avorn J. Relationship between COX-2 specific inhibitors and hypertension. Hypertension 2004; 44(1):1-5.
4. Schnitzer TJ, Burmester GR, Mysler E, et al. Comparison of lumiracoxib with naproxen and ibuprofen in the Therapeutic Arthritis Research and Gastrointestinal Event Trial (TARGET), reduction in ulcer complications; randomised controlled trial. Lancet 2004;364(9435): 665-74.
5. Page J, Henry D. Consumption of NSAIDs and the development of congestive heart failure in elderly patients. An underrecognized public health problem. Arch Intern Med 2000; 160: 777-84.
6. Mamdani M, et al. Cyclo-oxygenase-2 inhibitors versus non-selective non-steroidal antiinflammatory drugs and congestive heart failure outcomes in elderly patients: a population-based cohort study. Lancet 2004; 363:1751-56.
7. FitzGerald GA, Patrono C. The coxibs, selective inhibitors of cyclooxygenase-2. N Engl J Med 2001; 345(6):433-42.
8. Bombardier C, Laine L, Reicin A, et al. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group. N Engl J Med 2000; 343(21):1520-8, 2 p following 1528.
9. Ray WA, Stein CM, Hall K, Daugherty JR, Griffin MR. Non-steroidal antiinflammatory drugs and risk of serious coronary heart disease: an observational cohort study. Lancet 2002; 359(9301):118-23.
10. Solomon DH, Glynn RJ, Levin R, Avorn J. Non-steroidal anti-inflammatory drug use and acute myocardial infarction. Arch Intern Med 2002; 162(10):1099-104.
11. Eidelman RS, Hebert PR, Weisman SM, Hennekens CH. An update on aspirin in the primary prevention of cardiovascular disease. Arch Intern Med 2003; 163(17):2006-10.
12. Ray WA, Stein CM, Daugherty JR, Hall K, Arbogast PG, Griffin MR. COX-2 selective non-steroidal anti-inflammatory drugs and risk of serious coronary heart disease. Lancet 2002; 360(9339):1071-3.
13. Graham DJ, Campen D, Hui R, et al. Risk of acute myocardial infarction and sudden cardiac death in patients treated with cyclo-oxygenase 2 selective and nonselective non-steroidal anti-inflammatory drugs: nested case-control study. Lancet 2005; 365 (9458):475-81.
14. Singh G, Mithal A, Triadafilopoulos G. Both selective COX-2 inhibitor and nonselective NSAIDs increase the risk of acute myocardial infarction in patients with arthritis: selectivity is with the patient, not the drug class. Ann Rheum Dis. 2005; 64(suppl III):85.
15. Bresalier RS, Sandler RS, Quan H, et al. Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial. N Engl J Med 2005; 352(11):1092-1102.
16. Solomon SD, McMurray JJ, Pfeffer MA, et al. Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention. N Engl J Med 2005; 352(11):1071-80.
17. Food and Drug Administration. Advisory committee briefing document. January 12, 2005. Available at: http://www.fda.gov/ohrms/dockets/ac/05/briefing/ 2005-4090B1_03_pfizer-celebrex-bextra.pdf. Accessed February 21, 2007.
18. Bertagnoli MM, Eagle CJ, Zauber AG, et al. Celecoxib for the prevention of sporadic colorectal adenomas. N Engl J Med 2006; 355(9):873-84.
19. Arber N, Eagle CJ, Spicak J, et al. Celecoxib for the prevention of colorectal adenomatous polyps. N Engl J Med 2006; 355(9):885-95.
20. Gislason GH, Jacobsen S, Rasmussen JN, et al. Risk of death or reinfarction associated with the use of selective cyclooxygenase-2 inhibitors and nonselective nonsteroidal antiinflammatory drugs after acute myocardial infarction. Circulation 2006; 113(25):2906-13.
21. McGettigan P, Henry, D. Cardiovascular risk and inhibition of cyclooxygenase. A systematic review of the observational studies of selective and nonselective inhibitors of cyclooxygenase 2. JAMA 2006; 296:1633-44.
22. Catella-Lawson F, Reilly MP, Kapoor SC, et al. Cyclooxygenase inhibitors and the antiplatelet effects of aspirin. N Engl J Med 2001; 345(25):1809-17.
23. MacDonald TM, Wei L. Effect of ibuprofen on cardioprotective effect of aspirin. Lancet 2003;361(9357):573-4.
24. Kurth T, Glynn RJ, Walker AM, Chan KA, Buring JE, Hennekens CH, Gaziano JM. Inhibition of clinical benefits of aspirin on first myocardial infarction by nonsteroidal antiinflammatory drugs. Circulation 2003; 108(10):1191-5.
25. Garcia Rodriguez LA, Varas C, Patrono C. Differential effects of aspirin and non-aspirin nonsteroidal antiinflammatory drugs in the primary prevention of myocardial infarction in postmenopausal women. Epidemiology 2000; 11(4):382-7.
26. Food and Drug Administration. Minutes of the joint meeting of the Arthritis Advisory Committee and the Drug Safety and Risk Management Advisory Committee, February 16-18, 2005. Available at: http://www.fda.gov/ohrms/dockets/ ac/05/minutes/2005-4090m1_Final.htm. Accessed February 21, 2007.
27. Food and Drug Administration. COX-2 selective (includes Bextra, Celebrex, and Vioxx) and nonselective non-steroidal anti-inflammatory drugs (NSAIDs). April 7, 2005; updated July 18, 2005. Available at: http://www.fda.gov/cder/ drug/infopage/cox2/default.htm. Accessed February 21, 2007.
28. Food and Drug Administration. Alert for healthcare professionals: vadecoxib (marketed as Bextra). April 7, 2005. Available at: http://www.fda.gov/cder/drug/infosheets/hcp/valdecoxibhcp.htm. Accessed February 21, 2007.